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Reply to “Do not de-escalate oncology care in oropharyngeal
cancer routinely”
Dr. Petr Szturz and Dr. Jan B. Vermorken have made impor-
tant remarks about our study “De-escalation of post-
treatment surveillance in oropharyngeal cancer.” They raise
potential concerns about de-intensifying routine follow-up
of oropharyngeal squamous cell carcinoma (OPSCC).
We suggest that follow-up of HPV-associated OPSCC
could be de-intensified 2 years after treatment, since the major-
ity of recurrences and toxicities present within 2 years.1,2 We
encourage rapid access consultation whenever new symptoms
arise. Our article did not support treatment de-escalation out-
side randomized, controlled studies.
The prognosis of HPV+ OPSCC is excellent, with 3-year
local and regional control over 90%.3,4 Dr. Szturz and
Dr. Vermoken refer to a study in which, after 3 years of
follow-up, the proportion of HPV+ OPSCC patients pre-
senting with distant metastases was only 1.5% (7 of 457).5
The number of routine imaging studies needed to detect one
late, asymptomatic distant failure of HPV + OPSCC is high.
Exposing all HPV+ patients to prolonged follow-up, and
repeated imaging, is not likely to produce significant survival
benefits for the minority of patients with poor prognosis.
Although atypical sites of distant metastases have been
reported in the literature, the most common sites are the
lungs, liver, and bone, irrespective of HPV status.1,6,7 In a
study by Fakhry et al median time to disease progression
was also similar in HPV+ and in HPV− OPSCC, supporting
close surveillance within the first 2 years in both groups.1
Whether early detection of distant metastasis in asymp-
tomatic HPV+ OPSCC patients is beneficial in terms of life
quality, psychosocial well-being, or survival is yet contro-
versial. In decelerating progression of incurable disease, the
potential survival advantage and treatment toxicity should
be carefully assessed in randomized, controlled studies.8
We agree that careful monitoring of treatment toxicity is
important. Intense follow-up during the first 2 years detects
the majority of side-effects, and a multidisciplinary team
should be available throughout follow-up for early interven-
tion. Traditional, clinical outpatient examinations could be
partly replaced by modern methods, such as web-based
screening tools, in detecting late side-effects. In the future,
carefully planned treatment de-escalation protocols hope-
fully decrease permanent morbidity.
Intense follow-up may be justified in patients with
reduced life management skills, or with lower capacity for
self-assessment. Reducing routine follow-up for fit, asymp-
tomatic patients improves availability for those who need
more guidance, or quick assessment because of new symp-
toms. In a strict, protocol directed follow-up patients may
unnecessarily wait for a scheduled appointment, even when
a rapid check-up is required.
The extent to which patient preferences should guide
cancer follow-up and imaging, or medical decision making
in general, is an interesting issue from the perspective of
health economics.9 Dr. Szturz and Dr. Vermoken refer to a
cross-sectional study by Mueller et al. In that study, the
majority of head and neck cancer patients favored fewer
visits than the current standard.10
We would like to thank Dr. Szturz and Dr. Vermoken for
their valuable comments, and editors of the Head and Neck
journal for the opportunity to respond to their letter.
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